Design, Synthesis and Biological Evaluation of Novel Small Molecules as Multi-target Enzyme Inhibitors

Topic Information

Dear Colleagues,

We are delighted to announce the initiation of a Topic, "Design, Synthesis and Biological Evaluation of Novel Small Molecules as Multi-target Enzyme Inhibitors", dedicated to exploring the dynamic intersection of synthetic organic chemistry and biology, with profound implications for diverse medical applications.

Within this specialized topic, our focus is on the synthesis and biological assessment of novel small molecules designed to inhibit multiple enzymes concurrently. Multi-target enzyme inhibitors offer a comprehensive treatment approach by simultaneously targeting multiple disease-related pathways, enhancing therapeutic efficacy. Their ability to mitigate drug resistance, improve selectivity, and potentially provide synergistic effects makes them promising candidates for treating complex diseases. Additionally, the versatility of these inhibitors allows for a more personalized treatment strategy, addressing the multifactorial origins of various medical conditions.

The synthesis process involves optimizing for favorable pharmacokinetic properties and target specificity, leading to a varied library of compounds. The potential applications of the target inhibitors extend into critical areas of medical research, including neurological disorders, the antimicrobial field, antidiabetic therapies, and so on.

We also welcome investigations into novel synthetic methodologies, recognizing their importance in developing innovative strategies to access multi-target inhibitors. Contributions in the form of reviews and original research papers are encouraged for publication. We invite your participation in creating a comprehensive collection of articles, promoting a deeper understanding of the synthesis and evaluation of small molecules with multi-target enzyme-inhibitory properties and the development of novel synthetic routes.

We eagerly anticipate and welcome your valuable contributions to advancing the discourse surrounding this exciting and rapidly evolving field.

Dr. Davide Moi
Prof. Dr. Daniele Passarella
Dr. Andrea Citarella
Topic Editors

Keywords

Participating Journals

Journal Name	Impact Factor	CiteScore	Launched Year	First Decision (median)	APC
BioChem biochem	-	-	2021	24.1 Days	CHF 1000	Submit
Biomolecules biomolecules	4.8	9.4	2011	16.3 Days	CHF 2700	Submit
Current Issues in Molecular Biology cimb	2.8	2.9	1999	16.8 Days	CHF 2200	Submit
Molecules molecules	4.2	7.4	1996	15.1 Days	CHF 2700	Submit
Pharmaceutics pharmaceutics	4.9	7.9	2009	14.9 Days	CHF 2900	Submit
Scientia Pharmaceutica scipharm	2.3	4.6	1930	31.4 Days	CHF 1000	Submit

MDPI Topics is cooperating with Preprints.org and has built a direct connection between MDPI journals and Preprints.org. Authors are encouraged to enjoy the benefits by posting a preprint at Preprints.org prior to publication:

1. Immediately share your ideas ahead of publication and establish your research priority;
2. Protect your idea from being stolen with this time-stamped preprint article;
3. Enhance the exposure and impact of your research;
4. Receive feedback from your peers in advance;
5. Have it indexed in Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers (2 papers)

Order results

Content type Publication Date

Result details

Normal Extended Compact

Journals

All BioChem Biomolecules CIMB Molecules Pharmaceutics Sci. Pharm.

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

Error

Oops... you haven't selected anything for export.

Ok

clear

26 pages, 5799 KiB  

Open AccessReview

Exploring the Benzazoles Derivatives as Pharmacophores for AChE, BACE1, and as Anti-Aβ Aggregation to Find Multitarget Compounds against Alzheimer’s Disease

by Martha Cecilia Rosales Hernández, Marycruz Olvera-Valdez, Jazziel Velazquez Toledano, Jessica Elena Mendieta Wejebe, Leticia Guadalupe Fragoso Morales and Alejandro Cruz

Molecules 2024, 29(19), 4780; https://doi.org/10.3390/molecules29194780 - 9 Oct 2024

Viewed by 1123

Abstract

Despite the great effort that has gone into developing new molecules as multitarget compounds to treat Alzheimer’s disease (AD), none of these have been approved to treat this disease. Therefore, it will be interesting to determine whether benzazoles such as benzimidazole, benzoxazole, and [...] Read more.

Despite the great effort that has gone into developing new molecules as multitarget compounds to treat Alzheimer’s disease (AD), none of these have been approved to treat this disease. Therefore, it will be interesting to determine whether benzazoles such as benzimidazole, benzoxazole, and benzothiazole, employed as pharmacophores, could act as multitarget drugs. AD is a multifactorial disease in which several pharmacological targets have been identified—some are involved with amyloid beta (Aβ) production, such as beta secretase (BACE1) and beta amyloid aggregation, while others are involved with the cholinergic system as acetylcholinesterase (AChE) and butirylcholinesterase (BChE) and nicotinic and muscarinic receptors, as well as the hyperphosphorylation of microtubule-associated protein (tau). In this review, we describe the in silico and in vitro evaluation of benzazoles on three important targets in AD: AChE, BACE1, and Aβ. Benzothiazoles and benzimidazoles could be the best benzazoles to act as multitarget drugs for AD because they have been widely evaluated as AChE inhibitors, forming π–π interactions with W286, W86, Y72, and F338, as well as in the AChE gorge and catalytic site. In addition, the sulfur atom from benzothiazol interacts with S286 and the aromatic ring from W84, with these compounds having an IC₅₀ value in the μM range. Also, benzimidazoles and benzothiazoles can inhibit Aβ aggregation. However, even though benzazoles have not been widely evaluated on BACE1, benzimidazoles evaluated in vitro showed an IC₅₀ value in the nM range. Therefore, important chemical modifications could be considered to improve multitarget benzazoles’ activity, such as substitutions in the aromatic ring with electron withdrawal at position five, or a linker 3 or 4 carbons in length, which would allow for better interaction with targets. Full article

(This article belongs to the Topic Design, Synthesis and Biological Evaluation of Novel Small Molecules as Multi-target Enzyme Inhibitors)

►▼ Show Figures

Figure 1

attachment

Supplementary material:
Supplementary File 1 (ZIP, 1745 KiB)

18 pages, 2383 KiB  

Open AccessArticle

The Effects of the Steroids 5-Androstenediol and Dehydroepiandrosterone and Their Synthetic Derivatives on the Viability of K562, HeLa, and Wi-38 Cells and the Luminol-Stimulated Chemiluminescence of Peripheral Blood Mononuclear Cells from Healthy Volunteers

by Mikhail N. Sokolov, Vladimir V. Rozhkov, Maria E. Uspenskaya, Darya N. Ulchenko, Vladimir I. Shmygarev, Vladimir M. Trukhan, Andrei V. Churakov, Nikolay L. Shimanovsky and Tatiana A. Fedotcheva

Biomolecules 2024, 14(3), 373; https://doi.org/10.3390/biom14030373 - 19 Mar 2024

Cited by 1 | Viewed by 1586

Abstract

In order to evaluate the role of substituents at 3-C and 17-C in the cytotoxic and cytoprotective actions of DHEA and 5-AED molecules, their derivatives were synthesized by esterification using the corresponding acid anhydrides or acid chlorides. As a result, seven compounds were [...] Read more.

In order to evaluate the role of substituents at 3-C and 17-C in the cytotoxic and cytoprotective actions of DHEA and 5-AED molecules, their derivatives were synthesized by esterification using the corresponding acid anhydrides or acid chlorides. As a result, seven compounds were obtained: four DHEA derivatives (DHEA 3-propionate, DHEA 3-butanoate, DHEA 3-acetate, DHEA 3-methylsulfonate) and three 5-AED derivatives (5-AED 3-butanoate, 5-AED 3,17-dipropionate, 5-AED 3,17-dibutanoate). All of these compounds showed micromolar cytotoxic activity toward HeLa and K562 human cancer cells. The maximum cytostatic effect during long-term incubation for five days with HeLa and K562 cells was demonstrated by the propionic esters of the steroids: DHEA 3-propionate and 5-AED 3,17-dipropionate. These compounds stimulated the growth of normal Wi-38 cells by 30–50%, which indicates their cytoprotective properties toward noncancerous cells. The synthesized steroid derivatives exhibited antioxidant activity by reducing the production of reactive oxygen species (ROS) by peripheral blood mononuclear cells from healthy volunteers, as demonstrated in a luminol-stimulated chemiluminescence assay. The highest antioxidant effects were shown for the propionate ester of the steroid DHEA. DHEA 3-propionate inhibited luminol-stimulated chemiluminescence by 73% compared to the control, DHEA, which inhibited it only by 15%. These data show the promise of propionic substituents at 3-C and 17-C in steroid molecules for the creation of immunostimulatory and cytoprotective substances with antioxidant properties. Full article

(This article belongs to the Topic Design, Synthesis and Biological Evaluation of Novel Small Molecules as Multi-target Enzyme Inhibitors)

►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

 

Error

Oops... you haven't selected anything for export.

Ok

clear

Displaying articles 1-2